Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Thomas Herzog, MD

Advertisement

Articles by Thomas Herzog, MD

Future Directions for Treatment of Ovarian Cancer

ByThomas Herzog, MD
January 20th 2021

Role of PARP Inhibition in Recurrent Ovarian Cancer

ByThomas Herzog, MD
January 20th 2021

Selecting Maintenance Therapy in Ovarian Cancer

ByThomas Herzog, MD
January 20th 2021

PAOLA-1 Trial

ByThomas Herzog, MD
January 20th 2021

PRIMA Trial

ByThomas Herzog, MD
January 20th 2021

SOLO-1 Trial

ByThomas Herzog, MD
January 20th 2021

Ovarian Cancer: FDA Approved PARP Inhibitors

ByThomas Herzog, MD
January 20th 2021

Role of Maintenance Therapy in Ovarian Cancer

ByThomas Herzog, MD
January 20th 2021

Genetic Testing for Ovarian Cancer

ByThomas Herzog, MD
January 20th 2021
Advertisement

Latest Updated Articles

  • Ovarian Cancer: FDA Approved PARP Inhibitors
    Ovarian Cancer: FDA Approved PARP Inhibitors

    January 20th 2021

  • Genetic Testing for Ovarian Cancer
    Genetic Testing for Ovarian Cancer

    January 20th 2021

  • Role of Maintenance Therapy in Ovarian Cancer
    Role of Maintenance Therapy in Ovarian Cancer

    January 20th 2021

  • Future Directions for Treatment of Ovarian Cancer
    Future Directions for Treatment of Ovarian Cancer

    January 20th 2021

  • PAOLA-1 Trial
    PAOLA-1 Trial

    January 20th 2021

  • Selecting Maintenance Therapy in Ovarian Cancer
    Selecting Maintenance Therapy in Ovarian Cancer

    January 20th 2021



Advertisement
Advertisement

Trending on CancerNetwork

1

Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma

2

What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism

3

Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC

4

FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors

5

Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us